Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 9/20 | 0.55 |
| ▸ | PRMT1 | Q99873 | 2/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20184760 | 0.88 | PRMT1 (0.64) | NISCHPRMT1LMNARECQL | |
| SCHEMBL23775778 | 0.79 | PRMT1 (0.44) | NISCHPRMT1 | |
| SCHEMBL14854534 | 0.78 | PRMT1 (0.47) | PRMT1 | |
| SCHEMBL13135587 | 0.77 | NISCH (0.86) | NISCHPRMT1LMNARECQL | |
| Hydrochloric Acid SCHEMBL5562588 | 0.76 | NISCH (0.83) | NISCHPRMT1LMNARECQL | |
| SCHEMBL5476725 | 0.75 | NISCH (0.79) | NISCHLMNARECQL | |
| SCHEMBL562867 | 0.74 | NISCH (0.53) | NISCHLMNA | |
| SCHEMBL14854499 | 0.73 | PRMT1 (0.61) | NISCHPRMT1 | |
| SCHEMBL548346 | 0.73 | NISCH (0.54) | NISCHPRMT1 | |
| Hydrochloric Acid SCHEMBL7050789 | 0.72 | LMNA (0.53) | NISCHPRMT1LMNARECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1945209-B1 | BROAD SPECTRUM ANTIBACTERIAL COMPOUNDS | US GOV AS REPRESENTED BY THE SECRETARY OF THE UNITED STATES ARMY AND THE U S ARMY MEDICAL RESEARCH (US) | 2018-05-30 | — | — | EP | disclosed |
| US-7994225-B2 | Combination of an antibiotic and a drug such as pentamidine or salts thereof to treat drug resistant eye and ear infections | REMPEX PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7994225-B2 | Combination of an antibiotic and a drug such as pentamidine or salts thereof to treat drug resistant eye and ear infections | REMPEX PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | disclosed |
| US-7947741-B2 | Use and administration of bacterial efflux pump inhibitors | MPEX PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-7947741-B2 | Use and administration of bacterial efflux pump inhibitors | MPEX PHARMACEUTICALS, INC. (US) | 2011-05-24 | — | — | US | disclosed |
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | SILICON VALLEY BANK | 2008-06-05 | — | — | US | disclosed |
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | SILICON VALLEY BANK | 2008-06-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132457-A1 | BACTERIAL EFFLUX PUMP INHIBITORS FOR THE TREATMENT OF OPHTHALMIC AND OTIC INFECTIONS | ABCB11, SLC47A2, SLC47A1 | NISCH 168/4885PRMT1 4691/4885LMNA 4256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.